PubMed Health⌕ Search

PubMed · 2633859

[Therapeutics using plants: medications based on plants].

Abstract

There has been renewed interest in the age-old practice of using plants to treat disease. The general public prefers to emphasize the side effects of modern drugs rather than consider the efficacy of the revolutionary changes in therapeutics over the past forty years. So the need to implement protective measures to prevent the uncontrolled use of herbal remedies is being discussed throughout Europe. It is impossible to confirm whether the suggested plants are just placebos but even if they were, the need for the doctor to resort to this form of therapy must be stressed because of its unquestionable success rate. However, it is vital that the doctor's and perhaps public education allow the precise recognition of cases in which this form of treatment should be formally prohibited.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Duchêne-Marullaz. 1989. [Therapeutics using plants: medications based on plants].. https://pubmed.ncbi.nlm.nih.gov/2633859/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Recurrence risk to offspring in extended multiplex schizophrenia pedigrees from a Pacific Island isolate.

Genetic transmission plays a major role in the pathogenesis of schizophrenia. Family, twin, and adoption studies have consistently shown that risks in relatives are many times greater than the general population risk of approximately 1%. McGue, Gottesman, and Rao (1983; Am J Hum Genet 35:1161-1178) calculated risk estimates of 12.8% for offspring and 3.5% for nieces/nephews of schizophrenia patients based on a large data set of Western European families. The present study evaluated corresponding risk levels in Palau, an isolated population in Micronesia where the prevalence of narrowly (broadly) defined schizophrenia is 1.99% (2.67%) and cases cluster in extended pedigrees, 20 of which contain 80% of affected individuals. We hypothesized that offspring in these extended families would have a higher risk for schizophrenia than offspring in smaller schizophrenia pedigrees from more genetically heterogeneous populations. RDC diagnostic data based on complete ascertainment of cases and their families covering the past two generations were used to quantify empirical recurrence risks in the offspring and nieces/nephews of Palauan schizophrenia patients. Risks to 1st- and 2nd-degree offspring were approximately double the rates found in the smaller Western European families: 23.4% in the offspring of an affected parent, 6.4% in offspring with one affected aunt/uncle, and 15.0% in offspring with two or more affected aunts/uncles. Recurrence rates in offspring of an affected parent were 1.6 times higher in males (27.9%) than in females (17.7%). The high risk levels we found in Palauan offspring reflect the elevated population prevalence, strong familial aggregation, and multi-lineal transmission pattern of schizophrenia in Palau.

Europe↗